Cocaine esterase (CocE) is a naturally occurring bacterial enzyme, and a very efficient protein catalyst for the hydrolysis of cocaine, and has previously been shown to protect rodents from the lethal effects of cocaine. The current studies were aimed at evaluating the capacity of a longer-acting mutant form (CocE T172R/G173Q; DM CocE) of CocE to protect against the lethal effects of cocaine, and alter ongoing i.v. cocaine self-administration in rats. A dose-response analysis revealed a dose-dependent suppression of cocaine-reinforced responding with 1.0 mg CocE T172R/G173Q producing saline-like rates of responding. The effects of 1.0 mg CocE T172R/G173Q on cocaine-reinforced responding were then compared to responding when saline was available for injection, while the selectivity of CocE T172R/G173Q's effects were assessed by evaluating the effects of 1.0 mg CocE T172R/G173Q on WIN-35065-2-reinforced and food-reinforced responding. Although 1.0 mg CocE T172R/G173Q suppressed responding maintained by 0.1 mg/kg/inj cocaine, a significant increase in responding was observed when responding was maintained by 1.0 mg/kg/inj cocaine resulting in a 10-fold rightward shift in the dose-response curve for cocaine self-administration at a dose that did not significantly alter responding maintained by either WIN-35065-2 or food. These findings demonstrate that a longacting form of CocE is effective at abruptly reducing the ongoing self-administration of low doses of cocaine, and provides a robust antagonism of cocaine's reinforcing effects.
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Introduction:
Cocaine abuse remains a significant public health problem with an estimated 2.4 million users within the past month, and approximately 1.7 million identified as dependent on, or abusers of cocaine within the past 12 months in the United States alone (SAMHSA, 2007) . Despite longstanding efforts, there are currently no approved pharmacologic therapies for the treatment of cocaine abuse. Difficulties in identifying compounds capable of selectively antagonizing cocaine's reinforcing effects are due, at least in part, to cocaine's primary mechanism of action as a monoamine uptake blocker and the inherent difficulties in antagonizing a blocker. Three main approaches have been taken towards the development of pharmacotherapies for cocaine abuse i) "agonist"-therapeutics, aimed at providing a replacement drug for cocaine (e.g., Grabowski et al., 2004) ; ii) cocaine antagonists, aimed at blocking cocaine at its site(s) of action (e.g., Newman et al., 2005; Rothman et al., 2008) ; and iii) modulators of cocaine, aimed at altering the effects of cocaine by acting at sites other than monoamine transporters (e.g., Mello, 1990; Roberts and Brebner, 2000; Platt et al., 2002; Dackis and O'Brien, 2003) . Although these strategies are capable of decreasing cocaine self-administration in laboratory animals and humans, each has been met with difficulties including poor behavioral selectivity and/or increased abuse liability.
Alternatively, a smaller, but significant effort has been made towards the development of protein-based pharmacotherapies aimed at altering the pharmacokinetics of cocaine, thus reducing the amount of cocaine that is able to reach its central site(s) of action. Currently two main pharmacokinetic strategies are being investigated, i) sequestration of cocaine in the periphery with cocaine-specific antibodies (e.g., Fox et al., 1996; Martell et al., 2005) , and ii) enhancing the clearance of cocaine through cocaine-specific enzymes or catalytic antibodies (e.g., Landry and Yang, 1997; Turner et al., 2002) . Despite the fact that significant and This article has not been copyedited and formatted. The final version may differ from this version.
JPET Fast Forward. Published on as DOI: 10.1124 at ASPET Journals on jpet.aspetjournals.org Downloaded from JPET# 150029 5 selective decreases in cocaine self-administration have been reported in rats (Fox et al., 1996; Mets et al., 1998; Baird et al., 2000) , significant hurdles remain for both pharmacokinetic approaches.
With respect to cocaine-specific antibodies, although the passive administration of cocainespecific antibodies has resulted in significant decreases in cocaine self-administration in rats (Fox et al., 1996; Carrera et al., 2000) , active immunization has only been shown to inhibit the reinstatement of responding following acute cocaine challenges, but not the ongoing selfadministration of cocaine (Carrera et al., 2000; Kantak et al., 2000) . In fact, active immunization of rats against cocaine has been shown to result in significant increases in cocaine intake, suggesting that cocaine-specific antibodies are easily surmounted by increasing cocaine intake when antibody titer levels are low (Carrera et al., 2000) . Despite these potential problems, a cocaine-specific vaccine has been moved into human studies with similarly promising results (Kosten et al., 2002; Martell et al., 2005) . In a fourteen-week dose-escalation study, increases in antibody titer levels were reported to be well tolerated, and corresponded to modest decreases in cocaine use, and a prolonged attenuation of cocaine's subjective effects (Martell et al., 2005) . Although significant decreases in cocaine-positive urines have been reported during vaccination when antibody titers are high, a 10-fold increase in cocaine-positive urines was observed during the eight-week period following vaccination when antibody levels were decreasing (Kosten et al., 2008) , further suggesting that cocaine-specific antibodies are surmountable when titer levels are low.
One approach to overcome this requirement for high antibody levels has been the development of catalytic antibodies, which catalyze the breakdown of cocaine to ecgonine methyl ester and benzoic acid; thus, allowing for the antibodies to circumvent the stoichiometric limitations of traditional antibodies. Although the catalytic cocaine antibody, mAb 15A10, has been shown to 6 produce significant and selective decreases in cocaine-reinforced responding in rats (Mets et al., 1998; Baird et al., 2000) , this effect was only observed with high doses (30 mg/kg) of mAb 15A10, likely due to the relatively poor catalytic efficiencies of mAb 15A10 (Kcat/Km; ~26-fold lower than native butyrylcholinesterase (BChE)). Alternatively, increased clearance of cocaine by cocaine-specific enzymes has also been investigated. Recent studies (Pan et al., 2005) have identified a mutant butyrylcholinesterase (CocH) with an improved catalytic efficiency (~456-fold greater than native BChE) sufficient to allow for the selective inhibition of the reinstatement of responding following an acute cocaine challenge following pretreatment with a low dose (2 mg/kg) of CocH (Brimijoin et al., 2008) , however, this enzyme has yet to be evaluated in ongoing cocaine self-administration procedures.
A bacterial cocaine esterase (CocE) has been identified with catalytic efficiencies ~800-fold greater than BCHE (Larsen et al., 2002; Turner et al., 2002) . WT CocE has been shown to protect, and reduce, the toxic effects of cocaine in rats (Cooper et al., 2006) and mice (Ko et al., 2007) , as well as the cardiovascular (Wood et al., submitted) and seizurogenic (Jutkiewicz et al., 2008 ) effects of cocaine in rats suggesting WT CocE can rapidly clear large amounts of cocaine from the body. Although WT CocE has proven to be highly effective at protecting rodents against acute cocaine toxicity, its relatively short half-life in vivo (t1/2 ~ 15 min; Cooper et al., 2006) likely limits its usefulness in the treatment of cocaine abuse. Recent attempts to improve CocE's duration of action through site-directed mutagenesis have identified a double mutant (DM; T172R/G173Q) form of CocE with a significantly improved in vivo half-life (t1/2 ~ 4.5 hr in mice) without significantly altering the enzyme's catalytic efficiency .
Self-administration procedures in laboratory animals have proven to be a valuable preclinical model for the assessment of reinforcing properties of drug and non-drug reinforcers, as well as the identification of therapeutics with the potential of decreasing drug use in humans (e.g., This article has not been copyedited and formatted. The final version may differ from this version. Carroll et al., 2006) . The current studies were aimed at evaluating the capacity of a longer acting CocE T172R/G173Q to protect rats from the lethal effects of cocaine, and to alter the ongoing self-administration of cocaine in rats. Rats were trained to respond for 0.1 mg/kg/inj cocaine under a fixed-ratio (FR) 5 schedule of reinforcement, and a dose-response analysis was conducted to determine the dose of CocE T172R/G173Q required to inhibit cocainereinforced responding. Following this analysis, the effective dose of CocE T172R/G173Q (1.0 mg/rat), as well as an equivalent dose of WT CocE were further evaluated for their capacity to alter responding reinforced by 0.1 mg/kg/inj cocaine, and compared to the rates and patterns of responding emitted when saline was substituted for cocaine. The capacity of 1.0 mg/rat CocE T172R/G173Q to alter responding maintained by higher doses of cocaine was also evaluated in rats trained to respond for 0.32 and 1.0 mg/kg/inj cocaine. Additionally, the selectivity of the effects of CocE T172R/G173Q on cocaine-reinforced responding were assessed by evaluating the capacity of 1.0 mg/rat CocE T172R/G173Q to alter responding that was reinforced by a nonhydrolysable cocaine analog, WIN-35065-2 (e.g., Cooper et al., 2006) , as well as liquid food.
These studies demonstrate the capacity of low doses of a long-acting form of CocE to selectively and robustly antagonize the ongoing self-administration of cocaine in rats while having no effect on responding that was reinforced by other drug or non-drug reinforcers, and they suggest that a suitable, long-acting form of CocE could prove to be a valuable tool in the treatment of cocaine abuse in humans.
This article has not been copyedited and formatted. The final version may differ from this version. and maintained in a temperature and humidity controlled environment, on a 12-h dark/light cycle with lights on at 7:00 AM. Rats that were used to determine in vivo duration of action were freefed, whereas rats that were involved in self-administration experiments were maintained with ~20g of food per day from 7 days post surgery until the end of the experiment. All studies were performed in accordance with the Guide for the Care and Use of Laboratory Animals, as adopted and promulgated by the National Institutes of Health, and all experimental procedures were approved by the University of Michigan Committee on the Use and Care of Animals.
Prevention of cocaine-induced convulsion and lethality by CocE T172R/G173Q. The capacity of CocE T172R/G173Q to prevent the convulsant and lethal effect of cocaine was assessed to provide a measure of the in vivo duration of CocE T172R/G173Q's actions. Rats under the skin and attached to stainless steel tubing, exiting the back through a metal tether button, which was sutured, to the muscle between the scapula. Rats were allowed 5-7 days to recover from surgery prior to the start of any experiments. Catheters were flushed with 0.2 ml of heparinized saline (100 U/ml) prior to the start of self-administration sessions as well as after the completion of the session to prolong the duration of catheter patency. (0.032, 0.1, 0.32, and 1.0 mg/rat; i.v.) to alter responding that was reinforced with 0.1 mg/kg/inj cocaine was evaluated. Twelve rats (n = 6 rats/dose) were exposed to two different doses of CocE T172R/G173Q with doses randomly administered on a mg/rat basis immediately prior to the start of the session with six rats also exposed to a single saline-substitution session. Doses of CocE T172R/G173Q and the single-session saline substitution were presented in random order, and separated by at least three sessions (or until responding stabilized).
Apparatus

Comparison of the effects of WT CocE and CocE T172R/G173Q on cocaine-reinforced
responding. Upon acquisition of stable responding for 0.1 mg/kg/inj cocaine, comparisons of the effects of CocE T172R/G173Q and WT CocE on 0.1 mg/kg/inj cocaine-reinforced responding were performed in six rats. Each rat was exposed to each of three pretreatments (saline substitution, 1.0 mg/rat WT CocE, and 1.0 mg/rat CocE T172R/G173Q), with manipulations presented in random order, and separated by at least three sessions (or until responding stabilized). The effects of 1.0 mg CocE T172R/G173Q (administered on a mg/rat basis) and saline substitution on responding maintained by 0.32, and 1.0 mg/kg/inj cocaine were assessed in a second group of six rats, with each rat exposed to both 1.0 mg/rat CocE T172R/G173Q and saline at both doses of cocaine with the doses of cocaine and order of manipulations randomly assigned.
Effect of CocE T172R/G173Q on WIN-35065-2-and liquid food-reinforced responding.
The effects of 1.0 mg/rat CocE T172R/G173Q on responding reinforced by 0.01 mg/kg/inj WIN-35065-2 or 50 μl liquid food (Ensure®) were assessed in separate groups (n=6/group). The effects of 1.0 mg/rat CocE T172R/G173Q on WIN-35065-2-reinforced responding were compared to responding maintained during a single-session saline substitution with manipulations made in random order and separated by at least three sessions (or until responding stabilized). Similarly, the effects of 1.0 mg/rat CocE T172R/G173Q on foodreinforced responding were compared to responding maintained during a session in which rats were allowed to respond for empty dipper presentations with manipulations made in random order and separated by at least three sessions (or until responding stabilized). Response stability was defined as three consecutive sessions with less than 20% difference in responding and no increasing or decreasing trend in the number of injections earned.
Drugs
Responding during sessions in which rats were pretreated with WT CocE, or CocE T172R/G173Q, were compared to responding during single session saline substitutions (or when responding resulted in empty dippers), and responding maintained by the baseline reinforcers (0.1 mg/kg/inj cocaine, 0.01 mg/kg/inj WIN-35065-2, or 50 μl liquid food); significant differences were determined by one-way ANOVA with post-hoc Bonferroni tests (GraphPad Prism). Quarter-life (QL) calculations were used as a measure of intra-session response patterning, and were calculated by dividing the time required for 25% of the total responses to be made by the total session length (60 min). QL values represent the mean ± S.E.M.
(n=6/group) as determined for sessions in which rats were pretreated with CocE, saline was substituted, or when food was removed, and compared to the QL values for the baseline sessions immediately preceding these sessions. Significant differences in QL values between baseline and treatment sessions were determined by two-tailed, paired t-tests (GraphPad Prism).
This article has not been copyedited and formatted. The final version may differ from this version. Prevention of cocaine-induced convulsion and lethality by CocE T172R/G173Q. Cocaine (180.0 mg/kg;i.p.) induced convulsion, followed by lethality in 100% of the PBS pretreated rats at all pretreatment times (1, 60, 120, and 240 min). Pretreatment with CocE T172R/G173Q, administered on a mg/kg basis, produced a dose-dependent inhibition of the occurrence of both convulsion and lethality following an LD100 dose of cocaine, with significant inhibition of both endpoints observed following 1 min pretreatments of 1.0 mg/kg (0.29 ± 0.002 mg/rat) CocE T172R/G173Q, 1 and 60 min pretreatments of 3.0 mg/kg (0.93 ± 0.01 mg/rat) CocE T172R/G173Q, and 1, 60, and 120 min pretreatments of 10.0 mg/kg (2.96 ± 0.04 mg/rat) CocE T172R/G173Q (Fig. 1) . The durations of protection from cocaine-induced convulsion (pretreatment time sufficient to result in a 50% reduction in the occurrence of convulsion) were ~15 min for 1.0 mg/kg, ~75 min for 3.0 mg/kg, and ~190 min for 10.0 mg/kg CocE T172R/G173Q, whereas the durations of protection from cocaine-induced lethality (pretreatment time sufficient to result in a 50% reduction in lethality following an LD100 dose of cocaine) were ~25 min for 1.0 mg/kg, ~80 min for 3.0 mg/kg, and ~220 min for 10.0 mg/kg CocE T172R/G173Q.
Dose-response analysis of CocE T172R/G173Q on cocaine-reinforced responding. The effects of various doses of CocE T172R/G173Q, administered on a mg/rat basis, on the ongoing self-administration of cocaine were assessed in rats trained to respond for 0.1 mg/kg/inj cocaine, and compared to sessions in which saline was substituted for cocaine. As shown in completing only 20 fixed-ratios per session. Pretreatment with CocE T172R/G173Q had biphasic effects on cocaine-reinforced responding with an increase in responding observed at a dose of 0.1 mg/rat (0.09 ± 0.0004 mg/kg; p<0.01), and dose-dependent decreases in responding observed when doses of 0.32 mg/rat (0.93 ± 0.01 mg/kg; p<0.05), and 1.0 mg/rat (2.97 ± 0.02 mg/kg; p<0.001) CocE T172R/G173Q were administered. Not only were significant decreases in cocaine-reinforced responding observed during sessions in which rats were pretreated with either 0.32 and 1.0 mg CocE T172R/G173Q, but these low levels of responding were similar to those observed during the single session saline substitution tests. Quarter-life (QL) values for the baseline sessions, as well as the sessions in which saline was substituted, or pretreatments of CocE T172R/G173Q was administered are shown in Table 1 . There were no significant differences in the mean QL values for the five baseline sessions (0.20 ± 0.01 -0.24 ± 0.02), suggesting that 0.1 mg/kg/inj cocaine maintained similar patterns of responding throughout the course of the experiments. Moreover, the patterns of responding during sessions in which rats were pretreated with 1.0 mg/rat CocE T172R/G173Q were similar to those observed during saline substitution (QL values = 0.10 ± 0.02; p<0.001 and 0.10 ± 0.03; p<0.05, respectively), with QL values significantly lower than the corresponding baseline sessions.
Effects of WT CocE and CocE T172R/G173Q on cocaine-reinforced responding. To examine the relationship between the duration of enzymatic activity and the capacity of CocE to alter the ongoing self-administration of cocaine rats were pretreated with equal doses of 1.0 mg/rat of the short-acting WT CocE (2.83 ± 0.01 mg/kg), and the longer-acting CocE T172R/G173Q (2.85 ± 0.02 mg/kg) immediately prior to the start of sessions in which responding was reinforced with 0.1 mg/kg/inj cocaine, and the overall rates and patterns of responding were compared to sessions in which either 0.1 mg/kg/inj cocaine, or saline were available for injection. As shown in Figure 3 , high rates of responding were maintained during were observed during sessions in which rats were pretreated with 1.0 mg/rat CocE T172R/G173Q with rates of responding no different than those that were maintained by saline, and rats generally earning fewer than 20 injections per session.
To further evaluate the effectiveness of CocE T172R/G173Q to alter cocaine-reinforced responding, rats were pretreated on a mg/rat basis with 1.0 mg CocE T172R/G173Q immediately prior to sessions in which rats were allowed to respond for cocaine (0.32 or 1.0 mg/kg/inj), and the overall rates and patterns of responding were compared to sessions in which either cocaine or saline were available (Fig. 3) . When 0.32 mg/kg cocaine was available for injection responding occurred at rates lower than those maintained by 0.1 mg/kg/inj cocaine, with rats generally earned about 40 injections. Rates of responding during saline substitutions were not significantly different than baseline sessions, or sessions in which rats were pretreated with 1.0 mg/rat (2.87 ± 0.03 mg/kg) CocE T172R/G173Q. Yet lower, but stable, rates of responding were obtained when responding was reinforced with 1.0 mg/kg/inj cocaine with rats generally earning about 20 injections per session. Pretreatment with 1.0 mg/rat (2.86 ± 0.02 mg/kg) CocE T172R/G173Q resulted in a significant increase in responding for 1.0 mg/kg/inj cocaine with rats earning on average 122 injections of per session (Fig. 3) ; none of these rats died. Increases in the number of injections earned were also observed following saline substitution (~35 injections; Fig. 3 ), however, rates of saline-maintained responding were not significantly different than when responding was reinforced with 1.0 mg/kg/inj cocaine. Figure 4 . When responding was reinforced with 0.1 mg/kg/inj cocaine, responding was initiated early in the session and maintained at relatively stable rates throughout the 60 min session (Fig 4A-C) , and there were no significant differences in the mean QL values for the three baseline cocaine sessions (0.20 ± 0.02 -0.26 ± 0.03; Table 2 ). As shown in Figure 4A , when saline was substituted for cocaine, responding occurred at rates roughly equivalent to when cocaine was available for injection during the initial portion of the session then slowed for the remainder of the session with mean QL values (0.06 ± 0.01; p<0.01) significantly lower than the QL values when responding was reinforced by 0.1 mg/kg/inj cocaine.
Although pretreatment with 1.0 mg/rat (2.83 ± 0.01 mg/kg) WT CocE did not alter the overall rates of responding for cocaine (Fig. 3 ), significant differences in intrasession responding were observed. As shown in Figure 4C , when 1.0 mg/rat WT CocE was administered prior to the session, responding for 0.1 mg/kg/inj cocaine slowed early in the session, but rapidly recovered to rates roughly equivalent to those observed in baseline sessions resulting in significantly
higher QL values (0.34 ± 0.04; p<0.01) as compared to sessions in which either 0.1 mg/kg/inj cocaine (QL value = 0.24 ± 0.04) or saline (QL value = 0.12 ± 0.03) were available for injection.
Unlike with WT CocE, pretreatment with 1.0 mg/rat (2.85 ± 0.03 mg/kg) CocE T172R/G173Q resulted in a significant decrease in cocaine-reinforced responding. Similar to the pattern of responding observed when saline was substituted for cocaine, pretreatment with 1.0 mg/rat CocE T172R/G173Q resulted in rates of 0.1 mg/kg/inj cocaine-reinforced responding that were roughly equivalent to those observed in baseline sessions for the first 5-15 min with lower rates of responding for remainder of the session (Fig. 4B) . Although QL values for sessions in which rats were pretreatment with 1.0 mg/rat CocE T172R/G173Q (0.07 ± 0.02; p<0.05) were significantly lower than baseline sessions in which responding was reinforced by 0.1 mg/kg/inj, these QL vales were no different than those obtained during saline substitution.
This article has not been copyedited and formatted. The final version may differ from this version. Unlike when responding was reinforced with 0.1 mg/kg/inj cocaine, when 0.32 mg/kg/inj cocaine was available responding occurred at high rates during the initial ~5 min of sessions, then slowed and occurred at a lower, but stable rate throughout the remainder of the session ( Fig. 4D-E) with mean QL values of 0.11 ± 0.02 (Table 2) . Although there were no significant differences in the patterns of responding maintained by 0.32 mg/kg/inj cocaine and saline, there was a statistical trend towards lower QL values when rats were pretreated with 1.0 mg/rat (2.87 ± 0.03 mg/kg) CocE T172R/G173Q compared to baseline patterns of responding for 0.32 mg/kg/inj cocaine (QL values = 0.11 ± 0.02, and 0.08 ± 0.01 for cocaine alone, and following CocE pretreatment, respectively; p = 0.07; Fig. 4D -E). Similar to when 0.32 mg/kg/inj cocaine was available, high rates of responding were observed during the initial few minutes of the sessions in which 1.0 mg/kg/inj cocaine was available, with lower, but stable rates of responding occurring for the remainder of the session (Fig. 4F-G) , and mean QL values of 0.05 ± 0.01.
Although rats actually earned more injections during the single session saline substitutions as compared to when responding was reinforced with 1.0 mg/kg/inj cocaine, the majority of the responding still occurred within the initial 5 min of the session, with responding slowing throughout the session as was observed during saline substitutions from the two lower doses of cocaine (Fig. 4A, 4D , and 4F), with a mean QL value of 0.09 ± 0.02. Conversely, 1.0 mg/kg/inj cocaine maintained high rates of responding throughout the 60 min session when rats were pretreated with 1.0 mg/rat (2.86 ± 0.02 mg/kg) CocE T172R/G173Q, with mean QL values significantly greater than those observed during baseline sessions in which responding was reinforced by 1.0 mg/kg/inj cocaine (QL value = 0.23 ± 0.05; p<0.001).
Effects of CocE T172R/G173Q on WIN-35065-2-and liquid food-reinforced responding.
To determine whether the suppression of cocaine-reinforced responding by CocE T172R/G173Q was a selective effect of the esterase's action on cocaine, or a non-selective 19 responding with a significant increase in the mean QL value (0.34 ± 0.02; p<0.05) observed following pretreatments with CocE T172R/G173Q (Fig. 5E ). Similar to 0.1 mg/kg/inj cocaine and WIN-35065-2, liquid food maintained high rates of responding that were stable throughout the experimental protocol, with mean QL values (0.24 ± 0.01 -0.25 ± 0.01) similar to those observed for drug reinforcers (Fig 5D and 5F ). Likewise, these high rates of responding were sensitive to the reinforcer as responding occurred at significantly lower levels when the reinforcer was omitted, with responding slowing over the course of the 60 min session, and mean QL values (0.08 ± 0.02; p<0.001) significantly lower than those observed when responding was maintained by food presentation (Fig. 5D) . However, as shown in Figure 5F , pretreatment with 1.0 mg/rat (2.88 ± 0.02 mg/kg) CocE T172R/G173Q did not alter the intrasession pattern of responding that was maintained by liquid food as there was no difference in the mean QL values obtained during baseline conditions (0.25 ± 0.01) and sessions in which rats were pretreated with CocE T172R/G173Q (0.24 ± 0.01).
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Discussion:
The current studies were aimed at evaluating the capacity of a longer-acting mutant form of CocE (CocE T172R/G173Q) to protect against the lethal effects of cocaine, and to alter the reinforcing effects of cocaine, WIN-35065-2, and food in the rat. Similar to reports in mice , CocE T172R/G173Q produced a dose-dependent inhibition of the cocaine-induced produced a 10-fold rightward shift of the dose-response curve for cocaine self-administration without affecting responding for other drug or non-drug reinforcers. Taken together, these studies provide strong evidence that the thermostable mutant form of the cocaine hydrolyzing enzyme, CocE T172R/G173Q is capable of providing not only long-lasting protection against the toxic effects of cocaine, but that it is also capable of inhibiting the reinforcing effects of cocaine in rats.
Similar to previous reports with WT CocE in rats and mice (Cooper et al., 2006; Ko et al., 2007) , CocE T172R/G173Q produced a dose-dependent protection against cocaine-induced convulsion and lethality. However, unlike WT CocE, which had an in vivo duration of action of approximately 15 min (Cooper et al., 2006) , a similar dose of 3.0 mg/kg (0.93 ± 0.01 mg/rat) CocE T172R/G173Q was capable of protecting rats for approximately 80 min. Although the duration of WT CocE's protective effects is sufficient to inhibit the lethal effects of cocaine (Cooper et al., 2006) , this relatively short duration of action was insufficient to alter the these findings suggest that the longer-acting CocE T172R/G173Q is capable of suppressing the ongoing self-administration of cocaine, but also that the duration of suppression is correlated with the in vivo duration of action of the cocaine-hydrolyzing enzymes.
In the current studies, cocaine maintained dose-dependent levels of responding with high rates of responding observed when 0.1 mg/kg/inj cocaine was available, and low, but stable rates of responding observed when 1.0 mg/kg/inj was available. Intermediate rates of responding were observed during the single session saline substitutions regardless of the maintenance dose of cocaine. Based on the fact that cocaine-and saline-maintained rates and intrasession patterns of responding were easily differentiated when responding was maintained by a relatively low dose of cocaine, the capacities of different doses of CocE T172R/G173Q to alter cocainereinforced responding were evaluated in rats responding for 0.1 mg/kg/inj cocaine. CocE T172R/G173Q had biphasic effects on cocaine-reinforced responding, with the lowest active dose of CocE T172R/G173Q (0.1 mg/rat = 0.29 ± 0.02 mg/kg) resulting in an increased rate of cocaine-maintained responding, and a dose-dependent and significant decreases in the number of cocaine injections earned following higher doses of 0.32 mg/rat (0.93 ± 0.01 mg/kg) and 1.0 mg/rat (2.97 ± 0.02 mg/kg) CocE T172R/G173Q. Not only did pretreatment with 1.0 mg/rat (2.97 ± 0.02 mg/kg) CocE T172R/G173Q decrease the total number of cocaine injections earned to an extent that was equal to or greater than that which was observed during saline substitution, but the patterns of cocaine-reinforced responding were more similar to those Although the high rates of responding maintained by 0.1 mg/kg/inj cocaine provided an ideal baseline to determine whether a sufficiently high dose of CocE T172R/G173Q could completely antagonize the reinforcing effects of lower doses of cocaine, stoichiometric limitations of enzymatic approaches to treat drug abuse necessitated the evaluation of CocE T172R/G173Q
against larger unit-doses of cocaine. Despite the fact that 1.0 mg/rat (2.85 ± 0.02 mg/kg) CocE T172R/G173Q inhibited responding maintained by 0.1 mg/kg/inj cocaine to saline-like levels, CocE Tr17R/G173Q (1.0 mg/rat = 2.87 ± 0.03 mg/kg) did not significantly alter the overall rates of responding for a moderate dose of 0.32 mg/kg/inj cocaine. However, it should be noted that although the overall rates of responding were not different, there was a trend towards lower QL values when rats were pretreated with 1.0 mg/rat CocE T172R/G173Q, suggesting that CocE T172R/G173Q slowed responding for 0.32 mg/kg/inj cocaine in the later portion of the session, as is seen with saline substitution. Conversely, when rats were allowed to respond for 1.0 mg/kg/inj cocaine pretreatment with 1.0 mg/rat (2.86 ± 0.02 mg/kg) CocE T172R/G173Q
resulted in large increases in responding, with an average cocaine intake during the CocE condition of greater than 122 mg/kg/hr. Not only did all of these rats survive, but the rates and intrasession patterns of responding for 1.0 mg/kg/inj cocaine were similar to those maintained by a 10-fold lower dose of cocaine (0.1 mg/kg/inj), suggesting that 1.0 mg/rat CocE T172R/G173Q and effectively reduced the functional dose of cocaine available for injection resulting in a 10-fold rightward shift in the reinforcing effects of cocaine. Importantly, these effects of CocE T172R/G173Q on cocaine-reinforced responding were observed at a dose that did not significantly alter rates of responding for the non-hydrolysable cocaine analog, WIN-35065-2, or liquid food. This behavioral selectivity is further supported by the fact that CocE T172R/G173Q (1.0 mg/rat = 2.86 ± 0.02 mg/kg) failed to affect the intrasession patterns of responding for liquid food, however, pretreatment with 1.0 mg/rat (2.88 ± 0.02 mg/kg) CocE T172R/G173Q did alter the patterns of responding for WIN-35065-2.
Although the rates of WIN-35065-2-reinforced responding were slowed during the initial portion of the session following pretreatment with CocE T172R/G173Q responding during later portions of the session typically occurred at near baseline rates. These effects of CocE T172R/G173Q
on the patterns of WIN-35065-2-reinforced responding were more similar to those observed with the short-acting WT CocE on 0.1 mg/kg/inj cocaine-reinforced responding than the longer acting CocE T172R/G173Q, suggesting that the effects of CocE T172R/G173Q were surmounted as the session progressed. Given the fact that it WIN-35065-2 is a cocaine analog that lacks the ester bond that is hydrolyzed by CocE, it is likely that the initial suppression of responding resulted from a sequestration of WIN-35065-2 by CocE T172R/G173Q which was later surmounted as might be predicted once blood levels of the non-hydrolysable cocaine analog, WIN-35065-2 were sufficiently high to saturate the cocaine binding site of CocE T172R/G173Q.
Although these are not the first studies to evaluate the protein-based pharmacokinetic approach to altering reinforcing properties of cocaine, they do suggest that longer-acting cocaine hydrolyzing enzymes, such as CocE T172R/G173Q, may have distinct advantages compared to other protein-based approaches (i.e., cocaine-specific vaccines, catalytic antibodies, and other hydrolyzing enzymes). For instance, although cocaine-specific vaccines have provided promising results in both rodents (Fox et al., 1996; Carrera et al., 2000; Kantak et al., 2000) and humans (Martell et al., 2005; Kosten et al., 2008) , their capacity to decrease the subjective and reinforcing effects of cocaine has generally been limited by the need for high levels of circulating antibodies. Moreover, significant increases in cocaine intake have been observed in both rats and humans when antibody levels are too low (Carrera et al., 2000; Kosten et al., 2008; Kantak et al., 2000; Martell et al., 2005) , an effect that may result in an increased risk for cocaine toxicity as the antibodies simply sequester the cocaine in the periphery, but do not increase its clearance. One approach to circumvent these problems has been the development of cocainespecific, catalytic antibodies, which not only bind cocaine in the periphery, but also catalyze its degradation to inactive metabolites (Landry et al., 1993) , a strategy that has been shown to inhibit cocaine self-administration at doses that did not alter responding reinforced by other drug and non-drug reinforcers (Mets et al., 1998; Baird et al., 2000) . However, due to the relatively poor catalytic efficiency of mAb 1510A (~26-fold lower than native BCHE) relatively large doses (12-30 mg/kg) were required to affect cocaine-reinforced responding. Recently a mutant butyrylcholinesterase with significantly improved catalytic efficiency (~456-fold greater than native BCHE; Pan et al., 2005) has been reported to selectivity inhibit the reinstatement of responding by acute cocaine challenge (Brimijoin et al., 2008) , however, it is unclear whether this enzyme would have similar effects on cocaine self-administration.
Although CocE T172R/G173Q suffers from some of the same limitations as cocaine-specific vaccines (i.e., the inhibitory effects of CocE T172R/G173Q are surmountable by larger unitdoses of cocaine), CocE T172R/G173Q possesses a distinct advantage compared to cocainespecific vaccines in that it continues to metabolize cocaine as long as it is active, thus reducing the potentially toxic effects of higher levels of cocaine intake. Additionally, CocE T172R/G173Q has advantages over other cocaine hydrolyzing proteins due to its superior catalytic efficiency (~800-fold greater than native BCHE; Larsen et al., 2002; Turner et al., 2002; Gao et al., 2008) , resulting in significant improvements in potency, and substantially larger rightward shifts of the cocaine dose-response curve as compared to mAb 1510A. Despite these promising effects of CocE T172/G173Q on cocaine's toxic and reinforcing properties, it is likely that further improvements to CocE will be required for the successful treatment of a chronic relapsing disease such as cocaine abuse. For instance, although CocE T172/G173Q represents a significant advancement towards extending the in vivo duration of action (~15x longer than WT CocE), significantly longer-acting enzymes would be required to reduce the need for frequent dosing. Moreover, although repeated exposure to CocE T172R/G173Q did not alter the effectiveness of CocE T172R/G173Q to affect cocaine self-administration in the current studies, previous studies have reported a modest loss of function following repeated exposure to the WT CocE in mice with high anti-CocE antibody titers (Ko et al., 2007) . Mutagenesis studies are currently underway to identify other mutant forms of CocE with even longer durations of action and reduced immunogenicity.
In summary, these studies describe a series of experiments that demonstrate the capacity of the longer-acting mutant, CocE T172R/G173Q to provide a long-lasting protection against cocaineinduced convulsion and lethality, and a dose-dependent and selective inhibition the ongoing self-administration of cocaine in rats. Not only did increasing doses of CocE T172R/G173Q decrease responding maintained by 0.1 mg/kg/inj cocaine to saline-like levels, but 1.0 mg/rat (2.87 ± 0.01 mg/kg) CocE T172R/G173Q produced a 10-fold rightward shift in the doseresponse curve for cocaine self-administration without affecting responding for other drug and non-drug reinforcers. In conclusion, these studies provide strong evidence to support the notion that cocaine-hydrolyzing enzymes, such as CocE T172R/G173Q, with high catalytic efficiencies, and prolonged durations of action are capable of selectively inhibiting the ongoing selfadministration of cocaine, and may prove to be a valuable strategy for the treatment of cocaine abuse in humans.
